On October 27, 2026, Kiniksa Pharmaceuticals International, plc reported its financial results for the third quarter of 2026. The company announced that total revenue for the quarter was $286.0 million, a significant increase compared to $180.9 million in the same period the previous year.
The company’s primary product, ARCALYST, drove this growth. Net product revenue for ARCALYST in Q3 2026 was $286.0 million, representing approximately 58% year-over-year growth. Kiniksa stated that this commercial execution has positioned the drug to achieve blockbuster status in 2026.
In terms of portfolio execution, Kiniksa reported that as of the end of Q3 2026, approximately 23% of the 14,000 annual multiple-recurrence patients were actively on ARCALYST treatment. Additionally, more than 5,450 prescribers have written prescriptions for the drug since its launch.
Kiniksa also provided updated financial guidance. The company now expects 2026 ARCALYST net product revenue to be between $1.045 billion and $1.050 billion. This range was raised from the previous guidance of between $980 million and $995 million.
Regarding operating expenses, Kiniksa expects 2026 Research and Development (R&D) expenses to be between $160 million and $170 million. The company also expects 2026 Selling, General, and Administrative (SG&A) expenses to be between $270 million and $280 million.
On the balance sheet, as of September 30, 2026, Kiniksa reported cash, cash equivalents, and short-term investments totaling $568.8 million, with no debt.
The company is currently enrolling patients in the PASTORALE pivotal Phase 3 trial of KPL-387, an investigational treatment for recurrent pericarditis. Kiniksa expects to release data from this trial in the second half of 2027.
